Pharmaceuticals market in Brazil among most attractive in the Americas, says BMI

Brazil's pharmaceutical market is one of the most promising and attractive in the Americas and globally, according to Business Monitor International's global Pharmaceuticals & Healthcare Business Environment Ratings for first-quarter 2010, in which the Latin American nation ranks 16th, among the top-scoring emerging markets.

The country's strong operating environment has led to high levels of foreign direct investment (FDI) from multinational drugmakers over the past three years. A key measure of Brazil's attractiveness is its market size and growth rate. Annual sales in Brazil equate to around $17 billion, making it the 11th largest market globally. Growth rates, meanwhile, have been consistently high over the past decade a factor BMI forecasts will also prevail over the next. Increasing per-capita spending remains a key challenge, in order to provide patients with access to higher-price products.

Good prospects for generics